Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab +/- Apatinib vs Chemotherapy in First-line PD-L1+ NSCLC
NCT04203485Phase 3Unknown
- Sponsor
- Hengrui
- Start
- Jun 2020
- Primary completion
- Mar 2022
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 3 trial of camrelizumab in non-small cell lung cancer (NSCLC), sponsored by Hengrui. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04203485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04203485.